作者其他论文
文献详情
Risk/benefit profile of panitumumab-based therapy in patients with metastatic colorectal cancer: evidence from five randomized controlled trials
外文标题:Risk/benefit profile of panitumumab-based therapy in patients with metastatic colorectal cancer: evidence from five randomized controlled trials
文献类型:期刊
作者:Tang, Na-Ping[1]  Li, Hua[2]  Qiu, Yun-Liang[3]  Zhou, Guo-Min[4]  Wang, Yan[5]  Ma, Jing[6]  Chang, Yan[7]  Mei, Qi-Bing[8]  
机构:[1]Northwestern Polytech Univ, Sch Life Sci, Dept Pharmacol, Xian 710072, Peoples R China.;Natl Shanghai Ctr New Drug Safety Evaluat & Res, Shanghai 201203, Peoples R China.;
[2]Natl Shanghai Ctr New Drug Safety Evaluat & Res, Shanghai 201203, Peoples R China.;
[3]Natl Shanghai Ctr New Drug Safety Evaluat & Res, Shanghai 201203, Peoples R China.;
[4]Natl Shanghai Ctr New Drug Safety Evaluat & Res, Shanghai 201203, Peoples R China.;
[5]Natl Shanghai Ctr New Drug Safety Evaluat & Res, Shanghai 201203, Peoples R China.;
[6]Natl Shanghai Ctr New Drug Safety Evaluat & Res, Shanghai 201203, Peoples R China.;
[7]Natl Shanghai Ctr New Drug Safety Evaluat & Res, Shanghai 201203, Peoples R China.;
[8]Northwestern Polytech Univ, Sch Life Sci, Dept Pharmacol, Xian 710072, Peoples R China.;Fourth Mil Med Univ, Sch Pharm, Dept Pharmacol, Xian 710072, Peoples R China.;
通讯作者:Mei, Qi-Bing;
年:2014
期刊名称:TUMOR BIOLOGY影响因子和分区
卷:35
期:10
页码范围:10409-10418
增刊:正刊
学科:临床医学
收录情况:SCI(E)(WOS:000344532700112)  (25053599)  
所属部门:生命学院
重要成果类型:重要期刊
被引频次:2
人气指数:1030
浏览次数:910
基金:Major Projects Foundation of the National Science and Technology of China [2012ZX09302002, 2012ZX09505001-003]; National Natural Science Foundation of China [81273603]; Shanghai Rising-Star Program [14QB1400400]
关键词:Panitumumab; Colorectal cancer; Metastatic; Efficacy; Adverse events
摘要:
This study aims to evaluate the risk and benefit profiles of panitumumab-based therapy (PBT) in patients with metastatic colorectal cancer (mCRC). Relevant randomized controlled trials were identified by searching PubMed, Medline, EMBASE and Cochrane Library. Data on progression-free survival (PFS), overall survival (OS), all grade and severe (grade >= 3) adverse events were extracted and pooled to calculate hazard ratios (HRs) and risk ratios (RRs) with 95 % confidence intervals (CIs). Number n ...More
0
评论(0 条评论)
登录